血清促卵泡激素水平是接受激素替代疗法患者骨密度的一个预测指标。

Serum follicle-stimulating hormone level is a predictor of bone mineral density in patients with hormone replacement therapy.

作者信息

Kawai Haruko, Furuhashi Madoka, Suganuma Nobuhiko

机构信息

Department of Obstetrics and Gynecology, Handa City Hospital, 2-29 Toyo-cho, Handa, Aichi 475-8599, Japan.

出版信息

Arch Gynecol Obstet. 2004 Mar;269(3):192-5. doi: 10.1007/s00404-003-0532-7. Epub 2003 Sep 12.

DOI:10.1007/s00404-003-0532-7

PMID:13680264

Abstract

METHODS

A retrospective study regarding the relationship between serum hormonal levels and bone mineral density (BMD) was performed in 125 women with hormone replacement therapy (HRT). Serum estradiol (E(2)), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and BMD were evaluated before and at 12 and 24 months of HRT.

RESULTS

There was a significant increase in E(2) and decrease in FSH at both 12 (E(2), 39.3+/-76.6 pg/ml to 71.0+/-67.9 pg/ml; FSH, 67.9+/-36.3 mIU/ml to 47.9+/-29.0 mIU/ml) and 24 months (E(2), 68.3+/-54.5 pg/ml; FSH, 45.3+/-24.4 mIU/ml). LH level was high at baseline (26.5+/-16.1 mIU/ml) and decreased at 12 months (22.9+/-14.0 mIU/ml). On the contrary, it increased from 12 to 24 months (27.4+/-14.9 mIU/ml). In the lumbar spine BMD, a significant rise was seen only in the first 12 months (0.933+/-0.157 g/cm(2) to 0.938+/-0.152 g/cm(2)). When percentage change was analyzed, a significant positive correlation was found between E(2) and BMD and a negative correlation between gonadotropin levels and BMD.

CONCLUSION

These data demonstrate that serum gonadotropin levels, especially FSH, are a good marker to predict BMD in women with HRT.

摘要

方法

对125例接受激素替代疗法（HRT）的女性进行了一项关于血清激素水平与骨密度（BMD）关系的回顾性研究。在HRT治疗前、治疗12个月和24个月时评估血清雌二醇（E₂）、黄体生成素（LH）、卵泡刺激素（FSH）和骨密度。

结果

在12个月（E₂，从39.3±76.6 pg/ml升至71.0±67.9 pg/ml；FSH，从67.9±36.3 mIU/ml降至47.9±29.0 mIU/ml）和24个月时（E₂，68.3±54.5 pg/ml；FSH，45.3±24.4 mIU/ml），E₂均显著升高，FSH均显著降低。LH水平在基线时较高（26.5±16.1 mIU/ml），在12个月时降低（22.9±14.0 mIU/ml）。相反，从12个月到24个月它又升高了（27.4±14.9 mIU/ml）。在腰椎骨密度方面，仅在最初12个月出现显著升高（从0.933±0.157 g/cm²升至0.938±0.152 g/cm²）。分析百分比变化时，发现E₂与骨密度之间存在显著正相关，促性腺激素水平与骨密度之间存在负相关。